<DOC>
	<DOCNO>NCT00904696</DOCNO>
	<brief_summary>Irritable bowel syndrome ( IBS ) common chronic functional gastrointestinal disorder characterise abdominal pain/discomfort , bloat alteration bowel function . This condition significantly impair quality life place large burden health care resource . Existing therapy IBS far satisfactory new therapy constantly seek . The pathogenesis IBS remain unclear . Imbalance intestinal microbiota consider one important etiologic factor IBS . That probiotic effective prevention treatment IBS support idea . Progut synbiotic : combination probiotic prebiotics . Probiotics viable beneficial bacteria normally present healthy digestive tract . Each capsule Progut contain 9 billion viable bacteria 8 different strain characteristic healthy normal gut microflora : Lactobacillus ( L. acidophilus , L. casei , L. lactis , L. bulgaricus ) ; Bifidobacterium ( B. longum , B. infantis B. bifidum ) ; Streptococcus thermophilus time manufacturing . To ensure survival bacteria , Progut encapsulate enteric-coated . The primary objective evaluate tolerability Progut treatment 1-3 capsules/day patient irritable bowel syndrome condition likely encounter standard general clinical practice outpatient clinic . The rationale study obtain tolerability data patient IBS Singapore . The secondary objective evaluate patient ' satisfaction symptom improvement Progut treatment .</brief_summary>
	<brief_title>Tolerability Effectiveness Progut Treatment Irritable Bowel Syndrome</brief_title>
	<detailed_description>This open-label , single arm post marketing surveillance study involve active treatment period minimum 3-week maximum 12-week duration . Treatment Progut discretion attend doctor decision independent study . This study recruit patient follow prescription Progut follow upto maximum 12 week . At Visit 1 ( Day 1 ) , eligible patient receive prescription Progut physician . Depending discretion attend physician , prescribed Progut treatment duration last 3 12 week . Safety Progut normal clinical use assessed end period . Perception effectiveness , tolerability treatment assess Day 8-15 use phone interview . On Visit 2 ( time Day 22 85 , depend duration treatment give schedule follow-up visit arrange attend physician ) , patient evaluate symptomatic improvement , perception effectiveness , tolerability satisfaction treatment , follow he/she formally exit study . This study design choose aim recruit rapidly large cohort patient representative population prescribe Progut . A total 50 patient include allow assessment patient 's tolerability Progut , well satisfaction perception effectiveness symptom response Singapore population .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Patients age 18 IBS diagnose presence follow symptom : abdominal pain , bloat constipation organic pathology exclude All patient would endoscopy do past 3 year exclude organic low gastrointestinal pathology . All patient would prescribe Progut ( 13 capsule per day ) physician . Women pregnant , intend become pregnant breastfeeding . Patients severe medical condition ( ) view investigator prohibit participation study Immunocompromised patient Hypersensitivity Progut</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Irritable bowel syndrome</keyword>
	<keyword>probiotic</keyword>
</DOC>